Key result
In a real-world cohort of 8,238 patients with an insertable cardiac monitor, 24% of devices were reprogrammed, with 82% of all reprogramming events occurring remotely.
Why the study?
The role of remote device programming for an insertable cardiac monitor (ICM) has yet to be described in a real-world setting.
Cohort (n=8,238)
Remote programming of insertable cardiac monitors is frequently utilized in real-world practice, primarily within the first month post-insertion, suggesting it is a useful tool for device optimization.
Remote ICM programming appears feasible initially; leaves open questions on safety, efficacy, and workflow impact.
Remote device programming may enable workflow efficiencies and reduce resource strains on clinics as well as patients. Although the remote patient management ecosystem has evolved, several challenges remain, and the role of remote device programming for an insertable cardiac monitor (ICM) has yet to be described in a real-world setting. The purpose of this study was to characterize the initial real-world use of remote programming of an ICM. The cohort included 8,238 patients with the LUX-Dx™ ICM (Boston Scientific, Marlborough, MA, USA) during the first year of commercial use, which is also the first year that remote programming was available for an ICM. A descriptive review of reprogramming events revealed that 24% of devices were reprogrammed and that 82% of all reprogramming events occurred remotely. Over 74% of first reprogramming events occurred within the first 30 days following device insertion, and nearly 80% of devices only had 1 reprogramming event. These early data support the hypothesis that remote programming of an ICM is a clinically useful tool that may improve the clinical experience of device programming optimization, especially within the first month following device insertion.
No takes yet. Share an insight, caveat, or question.
Mahajan et al. (2022) conducted a cohort in Patients with an insertable cardiac monitor (n=8,238). Remote programming of an insertable cardiac monitor was evaluated on Device reprogramming events. In a real-world cohort of 8,238 patients with an insertable cardiac monitor, 24% of devices were reprogrammed, with 82% of all reprogramming events occurring remotely.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: